Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.

Nguyen HL, Ruxrungtham K, Delaugerre C.

Intervirology. 2012;55(4):287-95. doi: 10.1159/000336658. Epub 2012 Mar 23.

PMID:
22456540
2.

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

Maïga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cissé M, Katlama C, Calvez V, Marcelin AG.

Antivir Ther. 2009;14(1):123-9.

PMID:
19320246
3.

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.

Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL 3rd, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR.

Antimicrob Agents Chemother. 2011 Oct;55(10):4552-9. doi: 10.1128/AAC.00157-11. Epub 2011 Aug 1.

4.

HIV-1 Group O Resistance Against Integrase Inhibitors.

Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Plantier JC, Brenner B, Wainberg MA.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):9-15. doi: 10.1097/QAI.0000000000000698.

PMID:
26017662
5.

Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.

Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M.

J Med Virol. 2011 May;83(5):751-9. doi: 10.1002/jmv.22047. Epub 2011 Feb 25.

PMID:
21360548
7.

The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.

Liang J, Mesplède T, Oliveira M, Anstett K, Wainberg MA.

J Virol. 2015 Nov;89(22):11269-74. doi: 10.1128/JVI.01881-15. Epub 2015 Aug 26.

8.

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.

Hassounah SA, Mesplède T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA.

J Virol. 2014 Sep 1;88(17):9683-92. doi: 10.1128/JVI.00947-14. Epub 2014 Jun 11.

9.

The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.

Oliveira M, Mesplède T, Moïsi D, Ibanescu RI, Brenner B, Wainberg MA.

AIDS. 2015 Nov;29(17):2255-60. doi: 10.1097/QAD.0000000000000866.

PMID:
26372484
10.

Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.

Lataillade M, Chiarella J, Kozal MJ.

Antivir Ther. 2007;12(4):563-70.

PMID:
17668566
11.

Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.

Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, Micheli V, Penco G, Carli T, De Luca A, Zazzi M; ARCA Collaborative Group.

Clin Microbiol Infect. 2012 Oct;18(10):E428-30. doi: 10.1111/j.1469-0691.2012.03917.x. Epub 2012 Jun 21.

12.

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vézinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2011 Dec;66(12):2827-30. doi: 10.1093/jac/dkr389. Epub 2011 Sep 19.

13.

In vitro analysis of the susceptibility of HIV-1 subtype A and CRF01_AE integrases to raltegravir.

Bellecave P, Malato L, Calmels C, Reigadas S, Parissi V, Andreola ML, Fleury H.

Int J Antimicrob Agents. 2014 Aug;44(2):168-72. doi: 10.1016/j.ijantimicag.2014.04.013. Epub 2014 Jun 2.

PMID:
24935032
14.

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, Gutierrez F, Viciana I, de Mendoza C.

Antiviral Res. 2011 Jun;90(3):164-7. doi: 10.1016/j.antiviral.2011.03.178. Epub 2011 Mar 23.

PMID:
21439330
15.
16.

Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.

Seki T, Suyama-Kagitani A, Kawauchi-Miki S, Miki S, Wakasa-Morimoto C, Akihisa E, Nakahara K, Kobayashi M, Underwood MR, Sato A, Fujiwara T, Yoshinaga T.

Antimicrob Agents Chemother. 2015 May;59(5):2596-606. doi: 10.1128/AAC.04844-14. Epub 2015 Feb 17.

17.

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.

Sierra S, Lübke N, Walter H, Schülter E, Reuter S, Fätkenheuer G, Bickel M, da Silva H, Kaiser R, Esser S; SnoB-Study group.

Med Microbiol Immunol. 2011 Nov;200(4):225-32. doi: 10.1007/s00430-011-0194-1. Epub 2011 Apr 8.

PMID:
21475993
18.

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.

Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, Soriano V, De Mendoza C.

J Antimicrob Chemother. 2010 Feb;65(2):320-6. doi: 10.1093/jac/dkp423. Epub 2009 Dec 9.

19.

Emerging patterns and implications of HIV-1 integrase inhibitor resistance.

Geretti AM, Armenia D, Ceccherini-Silberstein F.

Curr Opin Infect Dis. 2012 Dec;25(6):677-86. doi: 10.1097/QCO.0b013e32835a1de7. Review.

PMID:
23086187
20.

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.

Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, Burioni R, Lazzarin A, Clementi M.

J Antimicrob Chemother. 2013 Nov;68(11):2525-32. doi: 10.1093/jac/dkt220. Epub 2013 Jun 24.

Items per page

Supplemental Content

Write to the Help Desk